Raphael Merriman, MD
Transplant Hepatology · San Francisco, CANPI 1942258728
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 2 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. That places this record below the midpoint for transplant hepatology clinicians in CA, where the typical reported total is $2,997.
Across 2 payments — averaging $108.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Cook Medical LLC$112
- DJO, LLC$105
Across 72 payments — averaging $3971.35 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Intercept Pharmaceuticals, Inc.$164K
- Intercept Pharma Europe Ltd.$65K
- Gilead$57K
What the payments were for
- Food & beverage$217100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Cook Medical LLC | 1 | $112 |
| DJO, LLC | 1 | $105 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ECHOTIP INSIGHT$112
- DONJOY$105
- AIRCAST$105
How this compares
$217 in reported general payments places this provider in the 20th percentile of 39 transplant hepatology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XifaxanRifaximin | 111 | $438,059 |
| VemlidyTenofovir Alafenamide | 120 | $210,168 |
| Entecavir | 92 | $38,938 |
| VeltassaPatiromer Calcium Sorbitex | 23 | $34,155 |
| Tenofovir Disoproxil Fumarate | 62 | $30,693 |
| Ursodiol | 127 | $26,444 |
| Tacrolimus | 151 | $23,293 |
| EliquisApixaban | 13 | $8,436 |
| Valganciclovir Hcl | 27 | $6,060 |
| Mycophenolic AcidMycophenolate Sodium | 23 | $4,926 |
| EnuloseLactulose | 36 | $4,598 |
| Mycophenolate Mofetil | 46 | $4,462 |
| Lactulose | 52 | $2,637 |
| Budesonide EcBudesonide | 11 | $1,955 |
| Azathioprine | 43 | $1,911 |
Paid to pharmacies, not to this prescriber.
Other transplant hepatology in San Francisco
- Jennifer LaiSan Francisco$70K
- Kidist YimamSan Francisco$53K
- Bilal HameedSan Francisco$44K
- Jennifer PriceSan Francisco$11K
- Danielle BrandmanSan Francisco$7K
- Chanda HoSan Francisco$3K
- Edward HoltSan Francisco$3K
- Jin GeSan Francisco$2K
- Jennifer GuySan Francisco$245
- Adil WakilSan Francisco$96
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.